Subscribe
shutterstock_690219232
Katherine Welles / Shutterstock.com
28 May 2020AmericasSarah Morgan

MSD buys Themis as part of COVID-19 plans

Merck Sharp & Dohme (MSD) is pushing forward with three initiatives aimed at combating the COVID-19 pandemic, including the acquisition of vaccine company Themis Bioscience.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Merck & Co to buy $1bn stake in Seattle Genetics
16 September 2020   Merck & Co is set to make a $1 billion investment in biotech company Seattle Genetics, as the companies collaborate to develop and sell Seattle Genetics’ cancer therapy, ladiratuzumab vedotin.
Big Pharma
Merck KGaA wins injunction after MSD trademark suit
21 May 2020   The English High Court has finalised the terms of a trademark injunction against US pharmaceutical company Merck, Sharp and Dohme (MSD), in favour of German rival Merck KGaA.
Big Pharma
Sanofi under fire over priority US access to COVID-19 vaccine
15 May 2020   Sanofi is facing criticism after CEO Paul Hudson said the US was likely to have priority access on any COVID-19 vaccine produced by the French pharmaceutical company.


Editor's picks

Astellas win strengthens blockbuster drug's European position
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

Editor's picks

Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025
Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

More on this story

Americas
Merck & Co to buy $1bn stake in Seattle Genetics
16 September 2020   Merck & Co is set to make a $1 billion investment in biotech company Seattle Genetics, as the companies collaborate to develop and sell Seattle Genetics’ cancer therapy, ladiratuzumab vedotin.
Big Pharma
Merck KGaA wins injunction after MSD trademark suit
21 May 2020   The English High Court has finalised the terms of a trademark injunction against US pharmaceutical company Merck, Sharp and Dohme (MSD), in favour of German rival Merck KGaA.
Big Pharma
Sanofi under fire over priority US access to COVID-19 vaccine
15 May 2020   Sanofi is facing criticism after CEO Paul Hudson said the US was likely to have priority access on any COVID-19 vaccine produced by the French pharmaceutical company.

More on this story

Americas
Merck & Co to buy $1bn stake in Seattle Genetics
16 September 2020   Merck & Co is set to make a $1 billion investment in biotech company Seattle Genetics, as the companies collaborate to develop and sell Seattle Genetics’ cancer therapy, ladiratuzumab vedotin.
Big Pharma
Merck KGaA wins injunction after MSD trademark suit
21 May 2020   The English High Court has finalised the terms of a trademark injunction against US pharmaceutical company Merck, Sharp and Dohme (MSD), in favour of German rival Merck KGaA.
Big Pharma
Sanofi under fire over priority US access to COVID-19 vaccine
15 May 2020   Sanofi is facing criticism after CEO Paul Hudson said the US was likely to have priority access on any COVID-19 vaccine produced by the French pharmaceutical company.

More features

Sandoz blocked by UK court from seeking Xarelto profits
An update on patenting in Ukraine, Russia and Eurasia
The rise of pro-NPE and patent sentiment in the US
UPC sees rising small molecule litigation with Pfizer in the hot seat
Why the Caribbean cannabis economy is ripe for IP protection
China filings push rise in patent applications in Ireland
Brain disorder medtech rivals butt heads at ITC
The right formula: Minimising the cost of chemical and pharma patents